Unknown

Dataset Information

0

Improving the affinity of SL0101 for RSK using structure-based design.


ABSTRACT: Enhanced activity of the Ser/Thr protein kinase, RSK, is associated with transformation and metastasis, which suggests that RSK is an attractive drug target. The natural product, SL0101 (kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside), has been shown to be a RSK selective inhibitor. However, the Ki for SL0101 is 1 μM with a half-life of less than 30 min in vivo. To identify analogues with improved efficacy we designed a set of analogues based on the crystallographic model of SL0101 in complex with the RSK2 N-terminal kinase domain. We identified an analogue with a 5″-n-propyl group on the rhamnose that has > 40-fold improved affinity for RSK relative to SL0101 in an in vitro kinase assay. This analogue preferentially inhibited the proliferation of the human breast cancer line, MCF-7, versus the normal untransformed breast line, MCF-10A, which is consistent with results using SL0101. However, the efficacy of the 5″-n-propyl analogue to inhibit MCF-7 proliferation was only two-fold better than for SL0101, which we hypothesize is due to limited membrane permeability. The improved affinity of the 5″-n-propyl analogue for RSK will aid in the design of future compounds for in vivo use.

SUBMITTER: Mrozowski RM 

PROVIDER: S-EPMC3601785 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Improving the affinity of SL0101 for RSK using structure-based design.

Mrozowski Roman M RM   Vemula Rajender R   Wu Bulan B   Zhang Qi Q   Schroeder Benjamin R BR   Hilinski Michael K MK   Clark David E DE   Hecht Sidney M SM   O'Doherty George A GA   Lannigan Deborah A DA  

ACS medicinal chemistry letters 20120201 2


Enhanced activity of the Ser/Thr protein kinase, RSK, is associated with transformation and metastasis, which suggests that RSK is an attractive drug target. The natural product, SL0101 (kaempferol 3-O-(3″,4″-di-O-acetyl-α-L-rhamnopyranoside), has been shown to be a RSK selective inhibitor. However, the Ki for SL0101 is 1 μM with a half-life of less than 30 min <i>in vivo</i>. To identify analogues with improved efficacy we designed a set of analogues based on the crystallographic model of SL010  ...[more]

Similar Datasets

| S-EPMC3331937 | biostudies-literature
2024-06-01 | GSE262739 | GEO
| S-EPMC2242497 | biostudies-literature
| S-EPMC2790991 | biostudies-literature
| S-EPMC11423305 | biostudies-literature
| S-EPMC2748254 | biostudies-literature
| S-EPMC10793902 | biostudies-literature
| S-EPMC3654563 | biostudies-literature
| S-EPMC8637584 | biostudies-literature
| S-EPMC10884402 | biostudies-literature